Page 41 Volume 18 - N.1 - 2010

Dor (2010) 18
17. Salzman RT, Roberts MS, Wild J, et al. Can a controlled-release oral 30. Fishbein M, Ajzen I. Belief, attitude, intention and behavior. An
dose form of oxycodone be used as readily as an immediate-release introduction to theory and research. Reading, MA: Addison-Wesley;
form for the purpose of titrating to stable pain control? J Pain Symp- 1975.
tom Manage. 1999;18:271-9. 31. Glajchen M. Chronic pain: treatment barriers and strategies for
18. Turk DC. Clinicians’ attitudes about prolonged use of opioids and clinical practice. J Am Board Faro Pract. 2001;14:211-8.
the issue of patient heterogeneity. J Pain Symptom Manage. 1996;11: 32. Veterans Health Administration DoD. VA/DoD clinical practice
218-30. guideline for the management of opioid therapy for chronic pain.
19. Urban BJ, France RD, Steinberger EK, et al. Long-term use of nar- Washington, DC: Veterans Health Administration, Department of
cotic/antidepressant medication in the management of phantom limb Defense; 2003.
pain. Pain. 1986;24:191-6. 33. World Health Organization. Cancer, pain relief and palliative care.
20. Gardner-Nix J. Principles of opioid use in chronic noncancer pain. Geneva, Switzerland: WHO; 1990. Report No. 408.
CMAJ. 2003;169:38-43. 34. Davis MP, Varga J, Dickerson D, et al. Normal-release and controlled
21. Gourlay DL, Heir HA, Passik SD. Exploring the misconceptions: release oxycodone: pharmacokinetics, pharmacodynamics, and
opioids in pain management. Pharma Group; 2004 controversy. Support Care Cancer. 2003;11:84-92.
22. National Pharmaceutical Council, Inc. Pain: current understanding 35. Breivik H, Collett B, Ventafridda V, Cohen R, Gallacher D. Survey of
of assessment, management and treatments [monograph]. Joint chronic pain in Europe: prevalence, impact on daily life and treat-
Commission on Accreditation of Healthcare Organizations; 2001. ment. Eur J Pain. 2006;10:287-333.
23. Weissman DE, Joranson DE, Hopwood MB. Wisconsin physicians’ 36. Simpson RK Jr, Edmondson EA, Constant CF, Collier C. Transdermal
knowledge and attitudes about opioid analgesic regulations. Wisc fentanyl as treatment for chronic low back pain. J Pain Symptom
Med J. 1991;90:671-5. Manage. 1997;14:218-24.
24. Portenoy RK. Current pharmacotherapy of chronic pain. J Pain 37. Caldwell JR, Hale ME, Boyd RE, et al. Treatment of osteoarthritis
Symptom Manage. 2000;19 Suppl 1:16-20. pain with controlled release oxycodone or fixed combination oxy-
25. Ajzen I. The Theory of Planned Behavior. In: Organizational behavior codone plus acetaminophen added to nonsteroidal antiinflamma-
and human decision processes. New York, NY: Academic Press, Inc; tory drugs: a double blind, randomized, multicenter, placebo con-
1991. p. 179-211. trolled trial. J Rheumatol. 1999;26:862-9.
26. Ajzen I, Fishbein M. Understanding attitudes and predicting social 38. Caldwell JR, Rapoport RJ, Davis JC, et al. Efficacy and safety of a
behavior. Englewood Cliffs, NJ: Prentice-Hall; 1980. oncedaily morphine formulation in chronic, moderate-to-severe os-
27. Francis JE, Johnston M, Walker A, et al. Constructing questionnaires teoarthritis pain: results from a randomized, placebo-controlled,
based on the theory of planned behaviour: a manual for health double-blind trial and an open-label extension trial. J Pain Symptom
services researchers. Newcastle upon Tyne, UK: Center for Health Manage. 2002;23:278-91.
Services Research; 2004. 39. Petty RE, Cacioppo JT. Attitudes and persuasion – Classic and
28. Gallagher R. Opioids in chronic pain management: navigating the contemporary approaches. Dubuque, IA: WC Brown Co. Publish-
clinical and regulatory challenges. J Fam Pract. 2004;53 Suppl ers; 1981.
10:23-32. 40. The American Pain Society (APS). Definitions related to the use of
29. Polit DF, Hungler BP. Nursing research: principles and methods. opioids for the treatment of pain [APS website], http://www.ampain-
6 ed. Philadelphia, PA: Lippincott; 1995. soc.org/advocacy/opioids2.htm.
th

DOR

40